A nationwide team led by researchers at Baylor College of Medicine, Texas Children's Hospital and UPMC Children's Hospital of ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

A nationwide team led by researchers at Baylor College of Medicine, Texas Children’s Hospital and UPMC Children's Hospital of ...

Researchers said a better understanding of barriers to bone health in hemophilia and VWD is needed, and guidelines should be ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...

Lentiviral vector (LV)–based gene therapy using CD34+ hematopoietic stem cells (HSCs) demonstrated stable factor VIII expression in severe hemophilia ... with peripheral-blood vector copy ...

The Union Health Ministry has launched the e-Blood Bank Portal, making it easier for patients and organisers to access blood ...

Fitusiran offers a 90% reduction in bleeding rates for hemophilia A or B with less frequent dosing than existing options. Phase 3 ATLAS trials showed significant efficacy, with many participants ...

By suppressing antithrombin (AT), a protein that inhibits blood clotting, Qfitlia promotes thrombin generation, which helps prevent bleeding episodes that plague those with hemophilia.

Overall, the near-term success of those ambitions will come down to a handful of new drug launches and a sickle cell disease ... Beyond hemophilia, the next frontier for Novo’s blood disorder ...